Conventional DCs specialize in activating naïve T cells, with cDC1s classically presenting exogenous peptides on MHC-I molecules to CD8+ T cells, where they generate cytolytic T cell responses capable of targeting both tumor and virally-infected cells. The gene discussed is CD8A; the disease is neoplasm.